All In Biotech

Drug Trial Radar · NCT04733118

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

393

Actual

Start

Aug 5, 2021

Primary completion

Mar 2027

Study completion Mar 2028

Sponsor

Lead sponsor
MedSIRAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hoffmann-La Roche
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous fixed-dose combination) and T-DM1, for patients with previously untreated HER2-positive early breast cancer.

Conditions

  • Early Breast Cancer

Interventions

  • Trastuzumab and Pertuzumab (FDC SC) and T-DM1Drug

    Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen. After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC. Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report: * Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles * Cohort B: T-DM1 ± ET for 10 cycles * Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year recurrence-free interval (3y-RFI)Time frame: 3 years
  2. Global health status declineTime frame: 1 year

Locations

41 sites in 5 countries. Site status is shown where the registry gives one.

  • UMHAT Sveti Ivan Rilski EAD Department of Medical Oncology

    Sofia, Bulgaria

  • Praxisnetzwerk Hämatologie und intern. Onkologie

    Cologne, Germany

  • Evangelisches Krankenhaus Bethesda

    Duisburg, Germany

  • Kliniken Essen Mitte

    Essen, Germany

  • Universitätsklinikum Essen Frauenklinik

    Essen, Germany

  • Universitätsklinikum Mannheim GmbH

    Manheim, Germany

  • Klinikum Ernst von Bergmann

    Potsdam, Germany

  • Békés county hospital

    Békés, Hungary

  • Tolna County Balassa János Hospital

    Szekszárd, Hungary

  • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola-Malpighi

    Bologna, Italy

  • AO Ospedale Civile Legnano

    Milan, Italy

  • Istituto Europeo di Oncologia - NC

    Milan, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, Italy

  • Ospedale Guglielmo da Saliceto

    Piacenza, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Centro Oncológico de Galicia

    A Coruña, Spain

  • Hospital Universitario A Coruña

    A Coruña, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Institut Català d' Oncologia Badalona (ICO)

    Badalona, Spain

  • Hospital Universitari Dexeus - Grupo Quirónsalud

    Barcelona, Spain

  • VHIO Vall d'Hebron Institute of Oncology

    Barcelona, Spain

  • Hospital Universitario de Basurto

    Bilbao, Spain

  • Consorcio Hospitalario Provincial De Castelló

    Castellon, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Spain

  • Complejo Hospitalario de Jaen

    Jaén, Spain

  • Complejo Asistencial Universitario de León

    León, Spain

  • Hospital Universitari Arnau de Vilanova de Lleida

    Lleida, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Quirón San Camilo- Ruber Juan Bravo

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario de Torrejón

    Torrejón, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, Spain

  • Hospital La Fe

    Valencia, Spain

  • Consorcio Hospital General de Valencia

    Valencia, Spain

  • Hospital Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • ICO L'Hospitalet - Instituto Catalán de Oncología

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.